Titan Medical Granted U.S. Patent for Robotic Surgical Instruments
March 27 2018 - 9:00AM
Titan Medical Inc. (“Titan” or the “Company”)
(TSX:TMD) (OTCQB:TITXF), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in minimally invasive surgery (“MIS”), today
announced it has been granted U.S. Patent No. 9,925,014, titled
“Actuator and Drive for Manipulating a Tool.” This patent is
a continuation patent from previously issued U.S. Patent No.
9,629,688 and covers the Company’s innovative single-port
multi-articulated instrument design and, specifically, an
orthogonally actuated instrument interface.
“We are pleased to report the granting of this
key patent as it further strengthens Titan’s intellectual property
position in single-port robotic surgery. The design and function of
the instrument interface provides a unique and potentially easier
instrument loading mechanism, and also facilitates close instrument
proximity to the surgical site at the point of insertion,”
commented David McNally, President and CEO of Titan Medical. “These
attributes enable successful single-port surgery by providing quick
instrument exchange through a small incision.”
Corresponding patent applications are pending in
various jurisdictions including China and Europe. With the issuance
of this patent, the Company has 23 issued patents and 48 pending
patent applications.
About Titan Medical Inc.
Titan Medical Inc. is focused on research and
development through to the planned commercialization of
computer-assisted robotic surgical technologies for application in
minimally invasive surgery. The Company is developing the SPORT
Surgical System, a single-port robotic surgical system. The SPORT
Surgical System is comprised of a surgeon-controlled patient cart
that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to pursue a broad set of surgical indications
for the SPORT Surgical System, including general abdominal,
gynecologic and urologic procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements, including statements with respect to
the use of the net proceeds of the Offering and the anticipated
listing of the Common Shares on the TSX, reflect management’s
current beliefs with respect to future events and are based on
information currently available to management. Forward-looking
statements involve significant risks, uncertainties and
assumptions. Many factors could cause the Company’s actual results,
performance or achievements to be materially different from any
future results, performance or achievements that may be expressed
or implied by such forward-looking statements, including, without
limitation, those listed in the “Risk Factors” section of the
Company’s Annual Information Form dated March 31, 2017 (which may
be viewed at www.sedar.com). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Sep 2023 to Sep 2024